Reference

Peptide research glossary: analytical and pharmacological terms

8 min read Last updated May 9, 2026By PrimeGen Research TeamBeginner

Plain-language definitions of the analytical, chemical and pharmacological vocabulary used across certificates of analysis, compound monographs and the research literature — from net peptide content and EC50 to lyophilization, deletion sequences and biased agonism.

In summary

Plain-language definitions of the analytical, chemical and pharmacological vocabulary used across certificates of analysis, compound monographs and the research literature — from net peptide content and EC50 to lyophilization, deletion sequences and biased agonism. This guide is published by PrimeGen Co., a United States supplier of lyophilized research peptides, and covers reference for laboratory research contexts only.

Topic:
Reference
Reading time:
8 min read
Sections:
Analytical terms · Chemistry and formulation terms · Pharmacological terms · Supply and compliance terms
Last updated:
May 9, 2026
Published by:
PrimeGen Co. research library
Scope:
Laboratory research use only — not medical guidance

Key takeaways

  • Most confusion in peptide sourcing comes from vocabulary, not chemistry.
  • Purity, potency, net peptide content and identity each answer a different question.
  • Knowing the terms on a certificate is what turns a document into evidence.

Analytical terms

Chromatographic purity. The area of the target peak as a percentage of total integrated peak area in an HPLC run at a stated wavelength. It measures composition among UV-absorbing species, not mass fraction of the vial.

Net peptide content. The proportion of the vial's contents that is peptide by mass, after accounting for residual water and counter-ions such as trifluoroacetate. Typically 75–90 percent for lyophilized material. This, not the label strength, is the figure used for accurate molar calculations.

Identity. Confirmation that the compound present is the compound named, established by mass spectrometry matching the observed mass to the theoretical mass of the stated sequence and its terminal modifications.

Deletion sequence. A chain missing one or more residues because a coupling step failed during synthesis. Chemically similar to the target and closely co-eluting, which is why purification rather than synthesis sets the achievable purity.

Lot. A discrete manufactured batch. Analytical data is only meaningful when tied to a specific lot number that matches the vial in hand.

Chemistry and formulation terms

Lyophilization. Freeze-drying: water is frozen and then removed by sublimation under vacuum, leaving an amorphous solid cake that is far more chemically stable than the same peptide in solution.

Reconstitution. Returning lyophilized material to solution by adding a diluent, normally bacteriostatic or sterile water, directed down the vial wall rather than onto the cake.

Counter-ion. The charged species paired with the peptide after purification, most often trifluoroacetate. It contributes mass without contributing peptide.

Amidation and acetylation. Terminal modifications that cap the C-terminus and N-terminus respectively, altering charge, mass and protease susceptibility. Both must be reflected in the theoretical mass on the certificate.

Excipient. Any non-peptide component added to a formulation, such as mannitol as a bulking agent. Research-grade peptides are frequently supplied without excipients, which is one reason cake appearance varies.

Pharmacological terms

Agonist. A ligand that binds a receptor and produces a response. A full agonist elicits the maximal response the system supports; a partial agonist plateaus below it and can behave as a functional antagonist when a full agonist is present.

EC50 and IC50. The concentration producing half the maximal effect, and the concentration producing half-maximal inhibition, respectively. Both are potency measures and neither describes the size of the maximal effect.

Efficacy. The magnitude of the maximal response a ligand can produce. Independent of potency: a more potent compound can be less efficacious.

Biased agonism. Preferential activation of one downstream pathway over another at the same receptor, classically G-protein signalling versus beta-arrestin recruitment. Two ligands with matched cAMP potency can differ substantially in receptor internalisation.

Half-life. The time for concentration to fall by half in a given system. Frequently engineered independently of receptor affinity through lipidation, albumin binding or protease-resistant substitutions.

Supply and compliance terms

Research use only (RUO). A designation indicating material is manufactured and released against research specifications and supplied for in vitro and appropriately approved preclinical work. It carries no sterility, endotoxin, GMP or regulatory safety evaluation.

Certificate of analysis (COA). A lot-specific analytical report. A complete one names the issuing laboratory, states the lot, the report date, the method conditions, the HPLC purity result and the mass-spectrometry identity result.

Third-party testing. Analysis performed by a laboratory independent of the manufacturer and the seller. Vendor-generated summaries without an independent issuer are not third-party data.

Retest or expiry date. The end of the period over which the material is expected to remain within its stated specification when stored as directed. It is a specification statement, not a safety claim.

Frequently asked questions

What is the single most misunderstood term on a certificate?
Purity. It is a chromatographic composition figure, not a statement about how much of the vial is peptide by weight. Net peptide content answers that question and is a separate line on a complete certificate.
Is potency the same as strength?
No. Strength on a vial label is the nominal fill weight in milligrams. Potency in pharmacology is the concentration required to produce a given effect, expressed as EC50 or IC50. The two are unrelated measures.

Related research compounds

Compounds covered by this article, each with its own monograph, specifications and lot-specific certificate of analysis.

About the author

PrimeGen Research Team

Analytical & technical writing, PrimeGen Co.

Our library is written in-house by the same team that reviews incoming lot analytics, reads third-party certificates of analysis and maintains compound documentation. Articles are educational reference material for laboratory professionals and describe published in vitro and preclinical literature only.

Published October 5, 2025 · Last reviewed May 9, 2026

References and further reading

  1. PubChem compound and substance databaseNational Center for Biotechnology Information
  2. Peer-reviewed literature index for peptide researchPubMed, U.S. National Library of Medicine
  3. Solid phase peptide synthesis (Merrifield, 1963)Journal of the American Chemical Society
  4. Guide to pharmacology — receptor and ligand referenceIUPHAR/BPS
  5. Research use only labelling and unapproved new drugsU.S. Food and Drug Administration

Where this fits in the Knowledge Center

Each hub sequences the guides, quality documentation and bench notes for a single topic, so you can move from this page into a structured reading path rather than a flat index.

Explore further

Move from this article into the catalog, the analytical documentation behind each lot, and the policies that govern every order.